Vir Biotech Shares Surge 35% and Ink $1.71B Astellas Collaboration
Vir Biotech agreed a $1.71 billion collaboration with Astellas for development of viral immunotherapies, including an undisclosed upfront payment and future milestones and royalties. Earlier the same day its shares jumped 35% on promising preliminary data for its prostate cancer therapy, fueling a surge in market capitalization.
1. Collaboration Details
Vir Biotech entered a $1.71 billion development and licensing agreement with Astellas covering its pipeline of viral immunotherapies, structured with an upfront payment plus potential clinical, regulatory and commercial milestones and tiered royalties.
2. Prostate Cancer Drug Reaction
Earlier the same day Vir's stock soared 35% after preliminary results from its prostate cancer candidate demonstrated encouraging efficacy signals in early-stage trials, sparking investor optimism about the therapy's commercial prospects.